MIS-416/immunogen (Innate)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameMIS-416/immunogen (Innate)
Drug Alias NameMIS-416/immunogen (Virionyx)anthrax vaccine (Virionyx)
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionNucleotide-binding oligomerization domain-containing protein 2 stimulantsToll like receptor 9 modulators
TargetsToll like receptor 9Nucleotide-binding oligomerization domain-containing protein 2
Therapy Area/IndicationsNeutropeniaNeoplasmsMalaria +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew Zealand
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAmplia Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAmplia Therapeutics Ltd
Active IndicationsN/A
Inactive IndicationsNeutropeniaNeoplasmsMalaria +[5] 

Other Information

ATC CodeN/A
Related LinksN/A